<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131142">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01934777</url>
  </required_header>
  <id_info>
    <org_study_id>OPBG-DHA, VIT E, CHOLINE</org_study_id>
    <nct_id>NCT01934777</nct_id>
  </id_info>
  <brief_title>EFFICACY AND TOLERANCE OF TREATMENT WITH DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis</brief_title>
  <official_title>STUDY OF EFFICACY AND TOLERANCE OF TREATMENT WITH DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this interventional study is to evaluate the efficacy and tolerability of
      docosahexaenoic acid (DHA), Vitamin E and Choline in children or adolescents with
      well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease (NAFLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty children or adolescents (4-16 years) with liver biopsy proven NAFLD will be enrolled.
      They will be randomized to treatment with DHA, VIT E and Choline (n=30)or an identical
      placebo (n=30) given orally for a period of 12 months. All patients will be included in a
      lifestyle intervention program consisting of a diet tailored on the individual requirements
      and physical exercise.

      Patients will undergo a medical evaluation every three months during the 12-month study
      period. Liver biopsy will be performed only at baseline  Anthropometric analysis, laboratory
      tests, including liver enzymes and lipids will be repeated at 3-month intervals during the
      12-months study duration. Ultrasonographyof the liver will be repeated after six months at
      the end of the study period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Liver status (steatosis and fibrosis) by ultrasonographic and fibroscan</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum alanine transferase levels</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum levels of triglycerides</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Liver Fibrosis</condition>
  <condition>Obesity</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>DHA,VITAMIN E, CHOLINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHA, VITAMIN E AND CHOLINE BY MOUTH EVERY DAY FOR 12 MONTHS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docosahexaenoic Acid, Vitamin E,  choline</intervention_name>
    <description>DHA, Vitamin E and Choline plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
    <arm_group_label>DHA,VITAMIN E, CHOLINE</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Docosahexaenoic Acid, Alpha tocopherol, choline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].</description>
    <arm_group_label>DHA,VITAMIN E, CHOLINE</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persistently elevated serum aminotransferase levels

          -  diffusely echogenic liver on imaging studies suggestive of fatty liver

          -  biopsy consistent with the diagnosis of NAFLD

        Exclusion Criteria:

          -  hepatic virus infections (HCV RNA-PCR negative)

          -  Hepatitis A, B, C, D, E and G

          -  cytomegalovirus and Epstein-Barr virus

          -  alcohol consumption

          -  history of parenteral nutrition

          -  use of drugs known to induce steatosis or to affect body weight and carbohydrate
             metabolism

          -  autoimmune liver disease, metabolic liver disease, Wilson's disease, and
             a-1-antitrypsin-associated liver disease were ruled out using standard clinical,
             laboratory and histological criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerio Nobili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bambino Gesù Children Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerio Nobili, MD</last_name>
    <email>nobili66@yahoo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bambino Gesù Hospital and Research Institute</name>
      <address>
        <city>Rome</city>
        <state>Rome, Italy</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valerio Nobili, MD</last_name>
      <phone>06/68592192</phone>
      <email>nobili66@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Valerio Nobili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 30, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bambino Gesù Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Valerio Nobili</investigator_full_name>
    <investigator_title>Head of Hepato-Metabolic Disease Unit, Bambino Gesù Children Hospital, IRCCS</investigator_title>
  </responsible_party>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>fibrosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
